The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomized design
High-dose vitamin D3 supplementation will reduce the risk of hospitalization/death among those with COVID-19 infection. The study involved 1500 newly diagnosed individuals with COVID-19 infection. They were randomized to either vitamin D3 (loading dose, then 3200 IU/day) or placebo. The primary outcome was the occurrence of hospitalization and/or mortality.

Related Post